Nathan Brown

Citée par

	Toutes	Depuis 2020
Citations	5998	3496
indice h	39	29
indice i10	59	42

820

410

205

615

2006200720082009201020112012201320142015201620172018201920202021202220232024202516 44 76 72 81 120 143 196 230 285 287 275 265 332 468 600 718 760 819 127

Accès public

Tout afficher

28 articles

6 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Marwin SeglerMicrosoft Research AI for ScienceAdresse e-mail validée de microsoft.com
Peter ErtlLeading Scientist at Ertl MolecularAdresse e-mail validée de peter-ertl.com
Sarah R. LangdonPhD Student, The Institute of Cancer ResearchAdresse e-mail validée de icr.ac.uk
Joshua MeyersProtein Engineering AI Lead, Synteny BiotechnologyAdresse e-mail validée de synteny.ai
Richard BaylissProfessor, University of LeedsAdresse e-mail validée de leeds.ac.uk
Yi MokBenevolentAIAdresse e-mail validée de benevolent.ai
Lewis R. VidlerComputational Medicinal Chemist, Eli Lilly and CompanyAdresse e-mail validée de lilly.com
Stefan KnappUniversity of FrankfurtAdresse e-mail validée de pharmchem.uni-frankfurt.de
Nicholas FirthAdresse e-mail validée de ucl.ac.uk
Richard A. LewisNovartis, BaselAdresse e-mail validée de novartis.com
Christos A NicolaouSenior Scientific Director, Computational Drug Discovery, Novo NordiskAdresse e-mail validée de novonordisk.com
Isaac WestwoodThe Institute of Cancer ResearchAdresse e-mail validée de icr.ac.uk
Jeremy L. JenkinsUS Head Discovery Sciences, Novartis BioMedical ResearchAdresse e-mail validée de novartis.com
Oleg FedorovUniversity of OxfordAdresse e-mail validée de cmd.ox.ac.uk
Panagis FilippakopoulosAssociate Professor, Oxford UniversityAdresse e-mail validée de sgc.ox.ac.uk
Fabio BroccatelliDirector at Altos LabsAdresse e-mail validée de altoslabs.com
George PapadatosHead of Data, Syngenta CP R&DAdresse e-mail validée de syngenta.com
Ruth BrenkUniversity of BergenAdresse e-mail validée de uib.no
Pascal FuretDirector and leading scientist at NovartisAdresse e-mail validée de novartis.com
Val GilletUniversity of SheffieldAdresse e-mail validée de sheffield.ac.uk

Suivre

Nathan Brown

Director of Digital Chemistry, Healx

Adresse e-mail validée de healx.ai

Digital Chemistry Chemoinformatics Cheminformatics Computational Chemistry Molecular Modelling


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
GuacaMol: benchmarking models for de novo molecular design N Brown, M Fiscato, MHS Segler, AC Vaucher Journal of chemical information and modeling 59 (3), 1096-1108, 2019	863	2019
Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites LR Vidler, N Brown, S Knapp, S Hoelder Journal of medicinal chemistry 55 (17), 7346-7359, 2012	325	2012
Bioisosteric replacement and scaffold hopping in lead generation and optimization SR Langdon, P Ertl, N Brown Molecular Informatics 29 (5), 366-385, 2010	246	2010
A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules N Brown, B McKay, F Gilardoni, J Gasteiger Journal of chemical information and computer sciences 44 (3), 1079-1087, 2004	244	2004
De novo molecular design and generative models J Meyers, B Fabian, N Brown Drug discovery today 26 (11), 2707-2715, 2021	239	2021
Multi-objective optimization methods in drug design CA Nicolaou, N Brown Drug Discovery Today: Technologies 10 (3), e427-e435, 2013	223	2013
Bioisosteres in medicinal chemistry N Brown Wiley. com, 2012	222	2012
Fragment-based hit identification: thinking in 3D AD Morley, A Pugliese, K Birchall, J Bower, P Brennan, N Brown, ... Drug Discovery Today 18 (23-24), 1221-1227, 2013	192	2013
On scaffolds and hopping in medicinal chemistry N Brown, E Jacoby Mini Reviews in Medicinal Chemistry 6 (11), 1217-1229, 2006	188	2006
A critical overview of computational approaches employed for COVID-19 drug discovery EN Muratov, R Amaro, CH Andrade, N Brown, S Ekins, D Fourches, ... Chemical Society Reviews 50 (16), 9121-9151, 2021	186	2021
Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening LR Vidler, P Filippakopoulos, O Fedorov, S Picaud, S Martin, M Tomsett, ... Journal of medicinal chemistry 56 (20), 8073-8088, 2013	167	2013
Artificial intelligence in drug discovery MA Sellwood, M Ahmed, MHS Segler, N Brown Future medicinal chemistry 10 (17), 2025-2028, 2018	165	2018
Scaffold Diversity of Exemplified Medicinal Chemistry Space SR Langdon, N Brown, J Blagg Journal of chemical information and modeling, 2011	165	2011
Plane of best fit: a novel method to characterize the three-dimensionality of molecules NC Firth, N Brown, J Blagg Journal of chemical information and modeling 52 (10), 2516-2525, 2012	147	2012
Artificial intelligence in chemistry and drug design N Brown, P Ertl, R Lewis, T Luksch, D Reker, N Schneider Journal of Computer-Aided Molecular Design 34, 709-715, 2020	142	2020
On the origins of three-dimensionality in drug-like molecules J Meyers, M Carter, NY Mok, N Brown Future medicinal chemistry 8 (14), 1753-1767, 2016	126	2016
Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript Z Kote-Jarai, A Amin Al Olama, D Leongamornlert, M Tymrakiewicz, ... Human genetics, 1-8, 2011	125	2011
Molecular optimization using computational multi-objective methods CA Nicolaou, N Brown, CS Pattichis Current Opinion in Drug Discovery and Development 10 (3), 316-324, 2007	121	2007
Chemoinformatics—an introduction for computer scientists N Brown ACM Computing Surveys (CSUR) 41 (2), 1-38, 2009	120	2009
Relationships between molecular complexity, biological activity, and structural diversity A Schuffenhauer, N Brown, P Selzer, P Ertl, E Jacoby Journal of chemical information and modeling 46 (2), 525-535, 2006	105	2006

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs